Washington/Mainz, Germany – A combination vaccine developed by Biontech/Pfizer that could be used to vaccinate against covid-19 and influenza simultaneously in the future has been placed in an accelerated approval process by the U.S. Food and Drug Administration. The announcement was made Friday by Biontech, a German company based in Mainz, and its U.S. partner Pfizer (New York).
The vaccine combines mRNA-based influenza with a Corona vaccine adapted to the currently prevalent BA.4/BA.5 omicron sublines and wild type.
In early November, the two companies announced the start of a Phase 1 trial of the vaccine. About 180 people between 18 and 64 were to participate in the U.S.
- source: APA/picture: pixabay.com
This post has already been read 84 times!